The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Positive results for acalabrutinib in Waldenström’s macroglobulinemia
BTK inhibition is a popular avenue of treatment research in Waldenström’s macroglobulinemia (WM). In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the recent trial (NCT02180724) exploring the efficacy of BTK inhibitor acalabrutinib monotherapy in both the frontline and relapsed/refractory settings. The data were overwhelmingly positive, with response rate and overall survival at 2 years both reaching more than 90%, and a relatively low toxicity. Finally, Prof. Rule touches upon the positive data from ibrutinib/rituximab combination therapies, and suggests that even better results might be achieved when acalabrutinib is also combined with rituximab.
